The Association for Laboratory Automation (ALA) announced the finalists for its $10,000 Innovation Award, which recognizes outstanding innovation and contributions to automation technologies in the laboratory.
Menveo, a vaccine in development by Novartis, may protect infants using a schedule beginning at two months of age against four of the most common causes of meningococcal disease.
Takeda Global Research & Development Center submitted a New Drug Application to the FDA for alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor under investigation for the treatment of type 2 diabetes.
The U.S. National Cancer Institute has filed a protocol for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal, or fallopian tube cancers using concurrent systemic and intraperitoneal administration of Reolysin, Oncolytics Biotech's’ formulation of the human reovirus.
LabAutomation2008 Show Preview Scientists and technology will converge in the desert at LabAutomation2008 to explore the latest in automation, high-throughput technologies, informatics, and more.
The XLC-3020FP fluorescence detector provides a signal-to-noise ratio with stability over a wide wavelength range (220-700 nm) for both excitation and emission.
Scientists from Supelco, a member of the Sigma-Aldrich group, have effectively extended the use of high-resolution LC by exceeding 120,000 plates/column under moderate operating conditions using commercial instrumentation.
Phenomenex Inc. introduces a new support and reference tool that helps chromatographers develop and optimize solid phase extraction (SPE) sample preparation methods.
A team from UCLA discovered that a gene linked to autism is most active in brain regions involved with language and thought.
In experiments with mice, researchers have found that the body's immune system can use a surprisingly common molecule to recognize prostate tumors.
Researchers at Johns Hopkins have discovered that at least one tumor suppressor gene is in fact turned off by a “noncoding” single stranded RNA nucleic acid similar to its double-stranded DNA cousin.
FDA approved 19 new medications in 2007, a decrease from 22 in 2006 and the lowest number since 1983.
Antisense therapy has been on a roller coaster ride since its inception. Is this heavyweight really down for the count?
Epigenetic changes are rapidly gaining acceptance as co-conspirators in carcinogenesis fueling the demand for DNA methylation assays.